Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis
Department
Medicine
Document Type
Conference Proceeding
Publication Title
Journal of Clinical Oncology
Conference Name
American Society of Clinical Oncology (ASCO) Annual Meeting
Conference Date
2025-05-30 - 2025-06-03
First Page
e23518
DOI
10.1200/JCO.2025.43.16_suppl.e23518
Volume
43
Issue
16_suppl
Publication Date
6-1-2025
Recommended Citation
Guntuku, S., Kasire, S. P., Doshi, K., Iyer, N., Byreddi, L. Y., Gouli, S., Paluri, R. K., Manne, A., & Kasi, A. (2025). Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis. Journal of Clinical Oncology, 43 (16_suppl), e23518. https://doi.org/10.1200/JCO.2025.43.16_suppl.e23518
COinS